ARWR - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals NASDAQ: ARWR executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets' 2026 Global Healthcare Conference.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Arrowhead Pharmaceuticals NASDAQ: ARWR is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference.
Arrowhead Pharmaceuticals presents a compelling bull case with a strong pipeline and a new commercialization status thanks to REDEMPLO FDA approval. ARWR's cardiometabolic pipeline, including REDEMPLO's potential updating and ARO-DIMER-PA's dual-target RNAi, supports future growth and market reach. The CNS drug ARO-MAPT that targets tauopathies linked to diseases like Alzheimer's will produce Phase 1 data in 2H 2026. This could drive a positive valuation rerating for ARWR.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong footing to continue to drive growth in the near-term with numerous opport.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH). “The early clinical data for ARO-PNPLA3 h.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the events in which it is scheduled to participate throughout the month of May, 2026.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate. FCS is a severe, rare disease characterized by triglyceride levels that can.
B. Metzler seel. Sohn and Co. AG purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 20,695 shares of the biotechnology company's stock, valued at approximately $1,374,000. Other institutional investors also recently
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) has adopted a positive opinion, recommending the approval of REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS remains widely underdiagnosed and affects an estimated 1 to.
Farther Finance Advisors LLC grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 2,923.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,941 shares of the biotechnology company's stock after acquiring an additional 11,546 shares
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia (HTG). The data were presented by Dr. Christie M. Ballantyne, MD, professor at Baylor College of Medicine, member of the Texas Heart Institute at Baylor, and Principal Inve.
Arrowhead Pharmaceuticals transitions from a 'show-me' pipeline to commercial stage, with its first approval for plozasiran in FCS. ARWR's valuation reflects a 5% downside, 10-15% base case upside, and up to 40% bull case upside, supporting a cautious buy rating. The investment thesis centers on a robust RNAi platform, late-stage cardiometabolic franchise, and significant near-term catalysts, notably SHTG phase 3 data.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing to multiple readouts concentrated in the third quarter and additional updates expected in the second half of the year. Multiple clinical catalysts expected in the third quarter Chief Executive
Citigroup Inc. decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 63.4% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,582 shares of the biotechnology company's stock after selling 89,204 shares during the period. Citigroup Inc.'s holdings in
GSK plc (GSK) is making a calculated bet on next generation gene silencing drugs, signing a licensing agreement worth up to $1 billion with China's Frontier Bio
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 Type: Fireside Chat Presentation Date/Time: March 2, 2026, 11:50 a.m. EST Leerink 2026 Global Healthcare Conference – March 8-11, 2026 Type: Fireside Chat Presentation Date/Time: March 9, 2026, 2:20 p.m. EST 2026 Jefferies Biotech on the Beach Summit – March 9-11, 2026.
China Universal Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 52.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,234 shares of the biotechnology company's stock after acquiring an additional 14,497 shares during